(Boursier.com) — inventive announces the selection of the abstract “Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH and Type 2 Diabetes, Correlated With Responses in Adiponectin Levels” for poster presentation at the 83rd Scientific Sessions of the American Diabetes Association held on June 23 to 26, 2023 in San Diego in the United States.
Adiponectin plays an essential role in energy homeostasis by regulating insulin sensitivity, lipid metabolism and blood sugar control. Also, adiponectin has anti-inflammatory and anti-fibrotic effects in the liver. Low levels of adiponectin are associated with several metabolic conditions, including type 2 diabetes (T2D) and NASH, and an increased risk of cardiovascular disease. PPAR signaling is implicated in disease pathways common to NASH and T2DM, and this abstract assesses the effect of the pan-PPAR agonist, lanifibranor, on adiponectin levels and improvement in markers of cardiometabolic health in patients with NASH and T2DM.
The Phase IIb clinical study, NATIVE, which evaluated lanifibranor in patients with non-cirrhotic NASH, demonstrated beneficial effects on liver histology, including resolution of NASH and regression of fibrosis. The authors of the abstract show that lanifibranor significantly increases adiponectin levels and that this increase correlates with improvements in cardiometabolic markers, including insulin resistance, glycemic control, lipid metabolism and systemic inflammation, in patients with NASH and T2DM or prediabetes.
©2023 Boursier.com